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AbstrAct
Objective
To describe a novel England-wide electronic health 
record (EHR) resource enabling whole population 
research on covid-19 and cardiovascular disease 
while ensuring data security and privacy and 
maintaining public trust.
Design
Data resource comprising linked person level records 
from national healthcare settings for the English 
population, accessible within NHS Digital’s new 
trusted research environment.
setting
EHRs from primary care, hospital episodes, death 
registry, covid-19 laboratory test results, and 
community dispensing data, with further enrichment 
planned from specialist intensive care, cardiovascular, 
and covid-19 vaccination data.
ParticiPants
54.4 million people alive on 1 January 2020 and 
registered with an NHS general practitioner in 
England.
Main Measures Of interest
Confirmed and suspected covid-19 diagnoses, 
exemplar cardiovascular conditions (incident stroke 
or transient ischaemic attack and incident myocardial 
infarction) and all cause mortality between 1 January 
and 31 October 2020.
results
The linked cohort includes more than 96% of the 
English population. By combining person level data 
across national healthcare settings, data on age, 
sex, and ethnicity are complete for around 95% of 
the population. Among 53.3 million people with no 
previous diagnosis of stroke or transient ischaemic 
attack, 98 721 had a first ever incident stroke or 
transient ischaemic attack between 1 January and 31 
October 2020, of which 30% were recorded only in 
primary care and 4% only in death registry records. 
Among 53.2 million people with no previous diagnosis 
of myocardial infarction, 62 966 had an incident 
myocardial infarction during follow-up, of which 8% 
were recorded only in primary care and 12% only in 
death registry records. A total of 959 470 people had a 
confirmed or suspected covid-19 diagnosis (714 162 
in primary care data, 126 349 in hospital admission 
records, 776 503 in covid-19 laboratory test data, and 
50 504 in death registry records). Although 58% of 
these were recorded in both primary care and covid-19 
laboratory test data, 15% and 18%, respectively, were 
recorded in only one.
cOnclusiOns
This population-wide resource shows the importance 
of linking person level data across health settings 
to maximise completeness of key characteristics 
and to ascertain cardiovascular events and covid-19 
diagnoses. Although this resource was initially 
established to support research on covid-19 and 
cardiovascular disease to benefit clinical care and 
public health and to inform healthcare policy, it can 
broaden further to enable a wide range of research.
Introduction
The covid-19 pandemic has increased awareness of the 
importance of population-wide person level electronic 
health record (EHR) data from a range of sources for 
examining, modelling, and reporting disease trends 
to inform healthcare and public health policy.1 Key 
benefits of research using such data on nationwide 
cohorts include generalisability of findings across all 
age groups, ethnicities, geographical locations, and 
socioeconomic, health, and personal characteristics, 
and inclusion of large numbers of people and events, 
enhancing the precision of findings and enabling a wide 
spectrum of novel research studies (eg, characterising 
shapes of relations between risk factors and disease, or 
studying minority groups and rare disease subtypes). 
While EHRs for whole country cohorts for Wales, 
Scotland, Denmark, and Sweden (populations of 3 
to 10 million) have been used in research for several 
years,2-6 at the start of the covid-19 pandemic, 
researchers had no access to national linked healthcare 
data across the population of England to enable critical 
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WhAt Is AlreAdy knoWn on thIs topIc
At the start of the covid-19 pandemic, approved researchers were unable to 
access national, linked health data across the whole UK population to conduct 
analyses that would support healthcare and public health policy
WhAt thIs study Adds
In partnership with NHS Digital, the British Heart Foundation Data Science 
Centre has developed a new trusted research environment for England, 
providing researchers with secure access to linked health data from primary and 
secondary care, registered deaths, covid-19 laboratory and vaccination data, and 
cardiovascular specialist audits
These datasets cover almost the entire population of England (>54 million 
people); similar linked data have been made available in trusted research 
environments for Scotland and Wales (>8 million people)
Large numbers of approved researchers are now accessing health data on almost 
all people in the UK to address important covid-19 related research questions
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research to support healthcare decisions and public 
health policy. There were two main reasons for this: 
the collection of comprehensive, linkable primary care 
data did not exist nationally and there was no secure, 
privacy protecting mechanism for researchers to access 
and conduct population-wide research using national 
datasets linked across different parts of the health 
data system (eg, from primary care, hospitals, death 
registries, laboratories). EHR research in England to 
date has therefore not been able to take advantage 
of the statistical power of studying a population of 
almost 60 million people, and clinical, public health, 
and policy insights have directly represented only a 
subset of the population. Hence there remains a need 
for accessible, nationwide health data in England 
for research, while ensuring participant safety and 
maintaining public trust.
Motivated by the public health importance of 
fully understanding the relation between covid-19 
and cardiovascular disease (CVD), the British Heart 
Foundation (BHF) Data Science Centre7 established 
the CVD-COVID-UK initiative.8 This partnership 
with national health data custodians in the four 
nations of the UK aims to provide linked, nationally 
collated EHRs for the whole population of the UK for 
approved research within secure, privacy protecting 
environments. Although established initially to 
support research into the impact of CVDs, and related 
treatment and risk factors, on covid-19 and the impact 
of covid-19 on CVDs, these linked EHR resources will, 
with appropriate ethical and regulatory approvals, be 
able to support a wide range of research studies. These 
could include investigations of the links between 
the full spectrum of risk factors and health states 
documented in EHRs and covid-19, the impact of the 
pandemic on health service activity and provision for 
non-covid-19 conditions, the nature and determinants 
of long covid, and the benefits and risks of covid-19 
vaccination. Research possibilities also include myriad 
studies of associations between risk factors and health 
outcomes beyond the pandemic, health and disease 
surveillance, quality assurance of health services, and 
planning recruitment to and follow-up in randomised 
trials.
In this paper we describe key features of the new 
English component of this UK-wide effort: a nationwide 
linked health data resource, provided within a new 
trusted research environment for England, developed 
in partnership with NHS Digital.9 We use descriptive 
analyses of the currently available data to illustrate the 
importance for whole population research studies of 
linking EHRs from across different health settings.
Methods
Data resources
The newly established NHS Digital Trusted Research 
Environment (TRE) for England provides researchers 
with secure, remote access to linked, person level 
EHR data from national health settings. The data 
sources currently available include primary care data, 
hospital episodes (covering inpatient, outpatient, 
emergency department, and critical care episodes), 
registered deaths (including causes of death), covid-19 
laboratory tests, and community dispensed medicines 
(table 1, fig 1, CVD-COVID-UK Dataset dashboard,10 
CVD-COVID-UK Dataset trusted research environment 
asset in Health Data Research Innovation Gateway).11 
Further incorporation of specialist intensive care, 
cardiovascular audit, hospital electronic prescribing, 
and covid-19 vaccination data are planned soon.
Supplementary figure 1 shows how data generated in 
hospitals, general practices, community pharmacies, 
covid-19 NHS and commercial testing services, 
covid-19 vaccination services, and registry offices 
flow to NHS Digital. Regular flows to NHS Digital of 
specialist intensive care and cardiovascular audit data 
from several different providers were established for the 
first time during 2020. Furthermore, the new primary 
care dataset established during spring 2020 by the GP 
Extraction Service, is the most comprehensive yet to 
flow to NHS Digital.
Data processing and linkage
The processing and quality checks applied by 
data providers and processors before arriving into 
and within NHS Digital vary by dataset (see notes 
accompanying supplementary figure 1 for full details). 
Linkage between datasets is enabled by NHS Digital’s 
Master Person Service,12 which aims to match multiple 
records with 99% accuracy for each person from 
different clinical computer systems (eg, hospitals and 
general practices) to a single unique identifier, the 
National Health Service number representing a single 
person. NHS numbers that are included in records 
are cross checked with associated personal details, 
including age, sex, and postcode, within the Personal 
Demographics Service. If the NHS number is verified, 
no further processing is required. If the NHS number 
cannot be verified or is not provided, the Master Person 
Service then attempts to match the records to a single 
NHS number held in the Personal Demographics 
Service. The Master Person Service checks the personal 
details in the submitted data file for closeness to the 
data held in the Personal Demographics Service and 
produces an associated match confidence score. Each 
unique person specific NHS number is replaced with 
a non-identifying unique master key (or pseudo-
identifier), which enables linkage of people’s records 
between datasets. At present this score is not provided 
at person level within each dataset, although work 
is ongoing within NHS Digital to enable this in the 
future. However, NHS Digital’s monthly reports for 
data quality maturity index indicate that 97-100% of 
records submitted to NHS Digital each month include 
information on NHS number and other key personal 
variables, providing confidence in the accuracy of the 
matching process.13
Data resource access: nHs Digital tre for england
On behalf of the CVD-COVID-UK consortium, the 
BHF Data Science Centre requested access to the data 
sources through the NHS Digital online Data Access 
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Request Service14 and received approval for the CVD-
COVID-UK research programme (reference No DARS-
NIC-381078-Y9C5K) following discussion with NHS 
Digital’s Independent Group Advising on the Release 
of Data (IGARD).15 A data sharing agreement with 
NHS Digital allows approved researchers based in UK 
research organisations (universities and NHS bodies) 
that jointly sign this agreement to access the data held 
within the NHS Digital TRE service for England.16 The 
BHF Data Science Centre coordinates an approvals 
and oversight board (including representation from 
NHS Digital, participating research organisations, 
and lay members), which ensures that research 
projects undertaken fall within the scope of the 
ethical and regulatory approvals for the CVD-COVID-
UK consortium programme. The trusted research 
environment provides secure storage and remote data 
access, avoiding the need for any person level data to 
leave NHS Digital (fig 1).
The NHS Digital TRE team provides named, approved 
researchers with secure log in details for remote access. 
Users of the trusted research environment can access 
data within NHS Digital’s data platform, where they 
can interrogate, manage, analyse, and visualise data 
using Databricks, a collaborative analytics platform 
that supports SQL and Python, and R Studio, a data 
analysis environment for R. Other analytical tools (eg, 
Stata) are to be made available soon. Flexible cloud 
compute is available through Amazon Web Services. 
The CVD-COVID-UK consortium’s data management 
and methods group has created user guides that explain 
how to navigate the environment; show where to find 
the data, data dictionaries, collaborative and personal 
work spaces and folders, and spaces for imported files 
(eg, phenotype code lists from external code libraries); 
and provide rules for database etiquette. NHS Digital 
hosts a regular user forum to consult with users on 
further developments in the NHS Digital TRE and 
table 1 | Overview of available and planned linked resources
availability of population-wide linked 
data, and data description Data resource
available january 2021
Primary care GDPPR: General Practice Extraction Service (GPES) data for pandemic planning and research
Hospital episodes Secondary Uses Service (SUS+) and Hospital Episode Statistics (HES) including: Emergency Care Dataset (ECDS), admitted  
participant care, adult critical care, and outpatients
Death registry Office for National Statistics (ONS) death registrations
Laboratory tests for covid-19 Public Health England (PHE) Second Generation Surveillance System (SGSS) test data results for covid-19 (pillars 1 and 2)
Community dispensing data NHS Business Services Authority (BSA) community dispensing data
to become available during 2021
Intensive care unit Intensive Care National Audit and Research Centre (ICNARC) data
Cardiovascular specialist audit  
and registry data
National Institute for Cardiovascular Outcomes Research (NICOR) datasets including: myocardial infarction national audit  
programme, adult percutaneous coronary interventions, national heart failure audit, cardiac rhythm management audit,  
congenital heart disease in children and adults, adult cardiac surgery audit, NICOR health technology registries 
Sentinel Stroke National Audit Programme (SSNAP) data 
National Vascular Registries (NVR) data
National covid-19 vaccination data National immunisation management system covid-19 vaccination dataset 
Adverse reactions dataset for covid-19 vaccination
Hospital electronic prescribing data
NHS Digital link datasets using NHS number + date of birth + sex
Public Health England
Covid-19 laboratory tests






• Community dispensing data
• Covid-19 vaccination data
• Hospital e-prescribing data
NHS Digital TRE for England
Cardiovascular specialist data
• National Institute for Cardiovascular
    Outcomes Research (NICOR) datasets
• Stroke audit (SSNAP)
• National vascular registry
Secure data �ows Secure access to deidenti�ed data and aggregate outputs
Secure storage and deidenti�cation of linked datasets Secure access for approved researchers
CVD-Covid-UK deidentified linked dataset
fig 1 | Overview of current (in bold) and planned data flows into nHs Digital trusted research environment (tre) for england
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runs a service to deal with problems and queries from 
users.
cvD-cOviD-uK consortium: aims, membership, and 
principles
The CVD-COVID-UK consortium aims to use analyses 
of UK population-wide linked EHR data to investigate 
the effects of CVDs, related risk factors, and treat-
ments on susceptibility to and poor outcomes from 
covid-19; the direct impact of SARS-CoV-2 infection 
on acute cardiovascular complications and longer 
term cardiovascular risk; and the indirect impact 
of the pandemic on the presentation, diagnosis, 
management, and outcomes of CVDs.8 Lay summaries 
of approved projects are published on the consortium’s 
web page.8 All consortium members (currently more 
than 130 people from 40 research or NHS organisations, 
including NHS data custodians) commit to: conducting 
research according to the “five safes”17; an inclusive 
approach that enables additional researchers to join 
the consortium as work evolves; and the open sharing 
of research protocols, analysis code, and phenotype 
code lists and algorithms (through the BHF Data 
Science Centre Github repository and, for phenotypes, 
the Health Data Research UK Phenotype Library).18 19
Researchers based in UK research organisations, 
including universities, NHS bodies, and charities, 
can join the consortium provided they are willing and 
able to agree to its principles, and they can access 
the data within the NHS Digital TRE provided their 
organisation is willing and able to sign the joint data 
sharing agreement with NHS Digital. A streamlined 
mechanism for requesting information and potential 
data access is available through the Health Data 
Research UK Innovation Gateway.11 The consortium 
does not currently have any members based in non-UK 
organisations and has not yet explored data access for 
such researchers with NHS Digital, but in the mean-
time it welcomes contributions from the international 
research community through collaboration with 
table 2 | Key details of main data resources
Primary care Hospital episodes Death registry




Name of resource GDPPR: General Practice 
Extraction Service (GPES) 
data for pandemic planning 
and research
Secondary Uses Service 
(SUS+)
Hospital Episode  
Statistics (HES) 
including: Emergency 
Care Dataset (ECDS), 
admitted participant 




(Office for National 
Statistics) asset)
Public Health England 
(PHE) Second  
Generation  
Surveillance System 
(SGSS) covid-19 test 
results




Who is included? People registered with a 
general practice in England, 
without a registered 
objection to sharing of data 
with NHS Digital, alive on 1 
November 2019
People receiving treatment 
or care at an NHS hospital 
in England
People receiving  
treatment or care at an 
NHS hospital in England
All people with a 
registered death in 
England
People with a  
laboratory confirmed  
polymerase chain  
reaction positive test 
result under pillar 1 or 
pillar 2 testing guidelines
People with at least 
one prescription 
dispensed in the 
community
What is recorded? Personal characteristics, 






(including ethnicity and 
area level deprivation), 
admission and discharge 




(including ethnicity and 
area level deprivation), 
admission and discharge 
dates, hospital and 
other variables
Date of death, date 
death was registered, 
sex, underlying cause 
of death, district,  
subdistrict, place of 
death (code,  
establishment, and type)
Personal characteristics 
(age, sex, ethnicity, lower 
layer super output areas), 
date of specimen,  







How are records 
coded?
SNOMED-CT ICD-10 (international  
classification of diseases, 
10th revision), OPCS-4  
(operating procedure 
codes, version 4)
ICD-10, OPCS-4,  
proprietary emergency 
care codes
ICD-10 Not coded British National  
Formulary  
Dictionary of  
Medicines and 
Devices
Period of record 
dates
From the earliest record for 
each person to present





Extracted fortnightly, up to 
date at time of each extract
Daily flows into NHS Digital, 
up to date on submission 
for completed episodes of 
care from submitting trusts
Updated monthly (from 
SUS) within NHS Digital, 
about 2 months behind 
real time
Weekly flows into NHS 
Digital, up to date at 
time of provision
Provided daily to NHS 
Digital, up to date at  
time of provision
Updated monthly, 
about 7-11 weeks 
behind real time




57 908 487 7 153 569 61 958 690 14 643 921 884 311 44 546 519
Total No of 
records
4 937 121 423 2 781 364 103 365 438 996 18 815 693 1 160 138 2 796 440 797
No of people 
known to be alive 
on 1 January 
2020
54 388 181 6 251 673 42 582 312 417 236 776 503 40 623 625
Total No of 
records among 
people alive on 1 
January 2020
4 870 642 482 2 491 646 379 228 933 294 457 412 988 174 2 329 914 169
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UK based consortium members (see supplementary 
annexe 1).
As a result of demand from researchers, in particular 
those addressing questions of critical policy relevance 
for the UK government chief scientific adviser’s national 
core studies programme, established to coordinate 
the UK’s covid-19 research response,20 the BHF Data 
Science Centre is currently seeking to extend the 
ethics and regulatory approvals for the consortium’s 
research programme. This will enable it to cover a 
comprehensive range of covid-19-relevant research 
that can be conducted using national linked EHRs.
Data updates
All the datasets are updated regularly within NHS 
Digital’s internal systems (between daily and 
fortnightly depending on the dataset) and have a 
variable lag behind real time at the point of update 
(table 2). The datasets are currently refreshed in the 
NHS Digital TRE on a synchronised monthly schedule, 
but more frequent updates (eg, weekly or daily) can 
be requested according to clinical, public health, and 
health policy research needs.
Data security, privacy, and confidentiality
The data within the NHS Digital TRE are deidentified 
(ie, directly identifying data items, such as each 
person’s name, address, NHS number, and exact date 
of birth, are removed) and pseudonymised (ie, each 
unique person specific NHS number is replaced with 
a non-identifying unique master key). Postcodes are 
replaced with lower layer super output areas that can 
be converted to indices of multiple deprivation.21 NHS 
Digital also operates a “safe outputs” service: although 
approved researchers work with record level and person 
level data within the trusted research environment, only 
summary, aggregate results can be extracted, subject 
to approval through disclosure control processes and 
rules, which follow similar principles to those used by 
other established trusted research environments, such 
as the Secure Anonymised Information Linkage (SAIL) 
Databank for Wales22 and the Scottish National Data 
Safe Haven.23 This ensures that no output that might 
be placed in the public domain contains information 
that could be used either on its own or in conjunction 
with other data to identify a person.
Derivation of participant characteristics and disease 
diagnoses
For descriptive analyses, we defined a linked cohort 
as all people in the primary care data known to be 
alive on 1 January 2020, excluding those who had 
either died before or were born on or after that date 
(as recorded in the death registry and in the primary 
care records, respectively). We censored follow-up 
on 31 October 2020, the latest common record date 
across the datasets. We defined eligible records within 
the hospital episodes, death registry, and covid-19 
laboratory test results as those that could be linked 
by their unique master key to a person included in the 
primary care data.
We combined primary care and hospital episodes 
records (covering inpatient, outpatient, emergency 
department, and critical care episodes) from before 
the index date of 1 January 2020 to define key 
characteristics, including sex, age, and ethnicity 
(categorised into white, mixed, Asian and Asian 
British, black and black British, and other ethnic 
groups). For each characteristic, we extracted the most 
recent record from the primary care data if available, 
otherwise we used the most recent record from the 
hospital episodes records. Characteristics were 
classified as “unknown” for people with no records. 
Using previously validated phenotypes from the 
CALIBER resource,24 we defined previous diagnoses of 
myocardial infarction (yes or no), stroke or transient 
ischaemic attack (defined as ischaemic stroke, 
haemorrhagic stroke, unspecified stroke, or transient 
ischaemic attack) (yes or no), diabetes (yes or no), and 
obesity (yes or no) from Systematized Nomenclature of 
Medicine Clinical Terms (SNOMED-CT) concept codes 
in the primary care data and from ICD-10 (international 
classification of diseases, 10th revision) codes in the 
hospital episodes (main or secondary diagnostic code 
position in the admitted patient care component of 
the Hospital Episode Statistics data) recorded before 
1 January 2020. For primary care phenotypes, we 
translated and expanded the phenotypes defined in 
Read Terms V2 to SNOMED-CT and cross referenced 
them with codes in the primary care dataset.25 Two 
clinicians independently reviewed all phenotype code 
lists and, when applicable, classified ICD-10 terms 
and SNOMED-CT concepts into prevalent or incident 
diagnoses (supplementary tables 1-4).19
We ascertained people with a first ever incident 
myocardial infarction or stroke or transient ischaemic 
attack as those with no diagnosis of myocardial 
infarction or stroke or transient ischaemic attack 
before 1 January 2020 and with a diagnosis SNOMED-
CT or ICD-10 code appearing in the primary care data, 
hospital episodes (main or secondary diagnostic code 
position in the admitted patient care component of 
the Hospital Episode Statistics data), or death registry 
(underlying or contributing cause of death) between 1 
January and 31 October 2020 (phenotype algorithms 
provided in supplementary tables 1 and 2).19
We ascertained people with a confirmed or suspected 
covid-19 diagnosis as those with a positive polymerase 
chain reaction or antigen test result from the covid-19 
laboratory test data, with a specimen date on or 
before 31 October 2020; or with a covid-19 diagnosis 
SNOMED-CT concept code appearing in the primary 
care data, with event date on or before 31 October 
2020; or with a diagnosis ICD-10 code appearing in the 
hospital episodes (main or secondary diagnostic code 
position in the admitted patient care component of the 
Hospital Episode Statistics), with admission date on or 
before 31 October 2020; or with a death registration 
including a diagnosis ICD-10 code (as underlying or 
contributing cause), with date of death on or before 
31 October 2020. Supplementary table 5 provides 
definitions for all covid-19 phenotypes.19
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This manuscript was prepared in accordance with the 
REporting of studies Conducted using Observational 
Routinely-collected Data (RECORD) guidance (see 
supplementary annexe 2).26
Patient and public involvement
The lay panel of the UK National Institute for Health 
Research-BHF Cardiovascular Partnership reviews the 
CVD-COVID-UK programme every few months and 
provides feedback that informs ongoing and future 
research. In addition, lay people directly affected by 
CVD are members of the consortium and its approvals 
and oversight board, enabling cogeneration of research 
ideas and providing valuable perspective and input 
on research proposals, lay summaries, and research 
outputs.
results
Overview of data resources
Table 2 provides an overview of the currently available 
primary care, hospital episodes, death registrations, 
covid-19 test data, and community dispensing data 
sources. Supplementary table 6 provides information on 
the data fields available, and definitions of these within 
each dataset, and supplementary table 7 summarises 
the codes included in the primary care dataset.
The primary care dataset includes healthcare 
information coded with SNOMED-CT concepts for all 
people registered with an English NHS general practice 
(excluding around 1.3 million people with a registered 
objection to their general practice records being 
provided to NHS Digital).25 The dataset includes data 
from 98% of all English general practices across all 
relevant general practice computer system suppliers 
(TPP, EMIS, In Practice Systems, and Microtest) and 
holds about 4.9 billion records on 54.4 million people 
alive on 1 January 2020 (>96% of the total population 
of England based on the UK Office for National 
Statistics mid-2019 population estimate for England 
of 56 286 961).27 Around 34 000 SNOMED codes are 
included (>90% of all those currently extracted for a 
wide range of purposes by NHS Digital’s GP Extraction 
Service), covering a broad range of diagnoses and 
procedures (from the start of each person’s records) 
along with laboratory results, physical measurements, 
clinical referrals, and prescriptions (supplementary 
table 7). Although more than 900 000 SNOMED codes 
are listed in UK and international releases, large 
numbers of these are either inactive or hardly used.
Administrative and clinical hospital episode data are 
available from both the Secondary Uses Service (SUS+) 
and Hospital Episode Statistics resources.27 These data 
table 3 | characteristics of linked cohort and of people with a confirmed or suspected covid-19 diagnosis, by data resource. values are numbers 




source of data on confirmed or suspected covid-19 diagnoses (% of subgroup)









 Women 27 718 313 (51.0) 400 448 (1.4) 424 870 (1.5) 57 789 (0.2) 22 532 (0.1)
 Men 26 661 385 (49.0) 313 558 (1.2) 351 383 (1.3) 68 329 (0.3) 27 716 (0.1)
 Unknown 8483 (0.0) 156 (1.8) 250 (2.9) 231 (2.6) 256 (3.0)
Age group (years):
 0-17 11 188 814 (20.6) 60 571 (0.5) 68 028 (0.6) 1827 (0.0) 9 (0.0)
 18-29 7 925 142 (14.6) 151 304 (1.9) 184 885 (2.3) 4081 (0.1) 70 (0.0)
 30-49 14 701 289 (27.0) 207 672 (1.4) 226 179 (1.5) 15 828 (0.1) 891 (0.0)
 50-69 13 026 860 (24.0) 179 977 (1.4) 181 399 (1.4) 35 070 (0.3) 6963 (0.1)
 ≥70 7 543 288 (13.9) 114 505 (1.5) 115 796 (1.5) 69 317 (0.9) 42 316 (0.6)
 Unknown 2788 (0.0) 133 (4.8) 216 (7.7) 226 (8.1) 255 (9.1)
Ethnicity:
 White 41 786 891 (76.8) 556 489 (1.3) 588 550 (1.4) 99 629 (0.2) 43 328 (0.1)
 Mixed 1 156 060 (2.1) 11 810 (1.0) 14 053 (1.2) 1748 (0.2) 433 (0.0)
 Asian and Asian British 4 589 778 (8.4) 95 752 (2.1) 108 455 (2.4) 13 317 (0.3) 3143 (0.1)
 Black and black British 1 860 340 (3.4) 20 863 (1.1) 25 051 (1.3) 6540 (0.4) 1684 (0.1)
 Other 2 138 019 (3.9) 14 334 (0.7) 18 962 (0.9) 3221 (0.2) 996 (0.0)
 Unknown 2 857 093 (5.3) 14 914 (0.5) 21 432 (0.8) 1894 (0.1) 920 (0.0)
Previous diagnoses:
  Stroke or transient  
ischaemic attack:
  No 53 191 717 (97.8) 685 197 (1.3) 745 978 (1.4) 108 596 (0.2) 39 427 (0.1)
  Yes 1 196 464 (2.2) 28 965 (2.4) 30 525 (2.6) 17 753 (1.5) 11 077 (0.9)
 Myocardial infarction:
  No 53 250 900 (97.9) 689 909 (1.3) 750 466 (1.4) 110 106 (0.2) 41 415 (0.1)
  Yes 1 137 281 (2.1) 24 253 (2.1) 26 037 (2.3) 16 243 (1.4) 9089 (0.8)
 Obesity:
  No 49 827 060 (91.6) 625 911 (1.3) 687 445 (1.4) 97 905 (0.2) 40 778 (0.1)
  Yes 4 561 121 (8.4) 88 251 (1.9) 89 058 (2.0) 28 444 (0.6) 9726 (0.2)
 Diabetes:
  No 50 778 499 (93.4) 642 095 (1.3) 700 133 (1.4) 88 262 (0.2) 33 283 (0.1)
  Yes 3 609 682 (6.6) 72 067 (2.0) 76 370 (2.1) 38 087 (1.1) 17 221 (0.5)
*From Hospital Episode Statistics-admitted patient care data.
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include information on length of stay, diagnoses, and 
procedures during hospital admissions as well as on 
outpatient, emergency department, and critical care 
episodes. Diagnoses are coded with ICD-10 codes and 
procedures with OPCS-4 (operating procedure codes, 
version 4).28 The SUS+ resource contains raw data 
collected from NHS healthcare providers, representing 
the most up-to-date hospital episodes within NHS 
Digital (among hospitals making prompt and complete 
returns). These data are consolidated, validated, and 
cleaned monthly to form the Hospital Episode Statistics 
database.29 As a result, each month’s Hospital Episode 
Statistics data become available about two months 
behind real time. Thereafter, a fixed update is produced 
for each full year of Hospital Episode Statistics data. 
Among the 54.4 million people included in our linked 
cohort, the SUS+ dataset holds 2.5 billion records for 
6.3 million people (from November 2019 onwards) 
and the Hospital Episode Statistics dataset holds 0.2 
billion records for 42.3 million people (from 1997 
onwards).
Death registration data11 flow daily to NHS Digital 
from the ONS civil registration dataset, including date, 
cause (coded with ICD-10), and place of death, and are 
available from April 1997. Deaths in England should 
be registered within five days of the date of death, 
although registration of a death is delayed in some 
situations.30 31 Among the 54.4 million people in our 
linked cohort, 417 236 died on or before 31 October 
2020.
The Second Generation Surveillance System 
(SGSS)11 is the national laboratory reporting system 
used in England to capture routine laboratory data on 
mainly infectious diseases, including SARS-CoV-2, and 
antimicrobial resistance. SGSS provides reports daily to 
NHS Digital on positive covid-19 test results (including 
the test date) fed directly from pillar 1 pathology 
laboratories (ie, established laboratories in hospitals 
for patients as well as NHS key workers) and indirectly 
from pillar 2 laboratories (ie, new, centralised, mostly 
privately run laboratories, created specifically for 
covid-19 testing for the wider population). By 31 
October 2020, a total of 884 341 people had at least 
one positive covid-19 test result recorded in the SGSS 
covid-19 laboratory test dataset, with 776 503 (88%) 
linkable to the 54.4 million person cohort.
The community dispensing dataset, provided 
monthly to NHS Digital by the NHS Business Services 
Authority, contains person level information on NHS 
primary care prescriptions dispensed by community 
pharmacists, appliance contractors, and dispensing 
doctors in England, including the name and strength 
of drug coded from the British National Formulary 
Dictionary of Medicines and Devices.32 Among the 
54.4 million person cohort, there were dispensed drug 
records for more than 40.6 million people and about 
2.3 billion records (from April 2018).
Personal characteristics and cvD incidence
Table 3 shows the characteristics of the linked cohort 
of 54.4 million people alive on 1 January 2020; 51% 
were women and 14% were aged 70 years or older, 
with a mean age of 40.0 years for men and 41.6 years 
for women. By linking and combining person level 
records from primary care and hospital episodes, 
ethnicity information is available for approximately 
95% of people, among whom 63% have their ethnic 
group recorded in primary care and 92% in hospital 
episodes data (fig 2). A previous diagnosis of stroke or 
transient ischaemic attack or of myocardial infarction 
is recorded for 2.2% and 2.1% of people, respectively, 
whereas 7% and 8% people have a record indicating a 
previous diagnosis of diabetes and obesity, respectively. 
Among 53.3 million people with no previous diagnosis 
of stroke or transient ischaemic attack, 98 721 had a 
first ever incident stroke or transient ischaemic attack 
between 1 January and 31 October 2020, 30% of which 
were recorded only in primary care (ie, not in hospital 
episodes or death registry data) and 4% only in death 
registry records (fig 2). Among 53.2 million people 
with no previous diagnosis of myocardial infarction, 
62 966 had an incident myocardial infarction during 
follow-up, 8% of which were recorded only in primary 
care and 12% only in death registry records (fig 2).
Diagnoses of covid-19
Among people in the linked cohort, 959 470 had a 
confirmed or suspected covid-19 diagnosis between 1 
January and 31 October 2020 (714 162 in primary care 
data, 126 349 in hospital admission records, 776 503 
in covid-19 laboratory test data, and 50 504 in death 
registry records). Although 58% of these were recorded 
in both primary care and covid-19 laboratory test data, 
15% and 18%, respectively, were recorded in only one 
(fig 3).
Although women were more likely to have a 
confirmed or suspected covid-19 diagnosis in their 
primary care records (1.4% women v 1.2% men and 
in covid-19 laboratory test data (1.5% v 1.3%), they 
were less likely to have a covid-19 diagnosis recorded 
in hospital episodes (0.21% v 0.26%) or on death 
certificates (0.08% v 0.10%). Older people were more 
likely to have a covid-19 diagnosis from hospital 
episodes and death registrations, although young 
adults were more likely to have covid-19 diagnoses 
recorded in covid-19 laboratory test data and primary 
care. People with unknown age or sex were more than 
10 times more likely to have a covid-19 diagnosis 
recorded in hospital episodes or on death certificates. 
A higher proportion of Asian and Asian British people 
had a covid-19 diagnosis in primary care and in the 
covid-19 laboratory test data compared with other 
ethnicities. Such differences were not, however, 
observed in information from hospital episodes or 
death certificates. People with a previous diagnosis 
of stroke or transient ischaemic attack, myocardial 
infarction, obesity, or diabetes were more likely to have 
a covid-19 diagnosis recorded in all healthcare settings 
(table 3).
When compared with the latest Public Health 
England reports of covid-19 laboratory test results,33 
covid-19 related hospital admissions,34 and deaths 
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with covid-19 on the death certificate,35 the data 
from our linked cohort concurs with those from 
relevant cumulative counts of people with covid-19 
(supplementary table 8).
discussion
We have described the development and key features 
of a novel linked EHR resource comprising a range of 
current and future planned linked datasets covering 
the entire population of England and forming part 
of a UK initiative to accelerate UK-wide research on 
covid-19 and CVD and beyond. We include descriptive 
analyses of a cohort of 54.4 million people alive at the 
start of 2020, including more than 96% of the English 
population. The datasets described are already being 
accessed through the new NHS Digital TRE service for 
England to enable an expanding range of research 
projects through the BHF Data Science Centre’s CVD-
COVID-UK consortium. Notably, combining person 
level information across data sources delivers about 
95% complete data on key characteristics, including 
age, sex, and ethnicity, and is essential for ascertaining 
CVDs of interest, such as stroke and myocardial 
infarction. About 90% of people with a positive 
covid-19 laboratory test result have linkable primary 
care records, and enriching the covid-19 laboratory 
test data with primary care, hospital episodes, and 
death registry data enables ascertainment of about 
20% additional people with confirmed or suspected 
covid-19.
comparison with other resources
Previously, research use of linked EHRs in England has 
been restricted to subsets of the population, according 
to the coverage of various data providers, including the 
individual primary care computer system suppliers (eg, 
Clinical Practice Research Datalink,36 Oxford-RCGP 
Research and Surveillance Centre,37 QResearch,38 and, 
more recently, OpenSafely39). Population coverage 
for each of these has increased during the pandemic. 
Supplementary table 9 provides a summary of the 
population based linked healthcare resources for 
England, which cover a population of more than five 
million people and include primary care data as an 
anchoring component. As the national provider of 
information, data, and IT systems for commissioners, 
analysts, and clinicians in health and social care in 
England, NHS Digital handles larger volumes of health 
data than any other organisation in the UK and has 
extremely well developed and robust processes for 
maintaining data security and privacy. Alignment 
of the new NHS Digital TRE for England with NHS 
Digital’s systems therefore maximises security 
while minimising the need for transmission of large 
volumes of linked data to support population scale 
research.
Number of participants with a reported
ethnicity (n=51 531 088, 95% of linked cohort)
98 721 people with a first ever stroke/TIA from
1 Jan-31 Oct 2020 (2.2 incident events per 1000 person years)
62 966 people with a first ever myocardial infarction from
1 Jan-31 Oct 2020 (1.4 incident events per 1000 person years)
Deaths






































fig 2 | Data sources reporting person level data on ethnicity, incident stroke or transient ischaemic attack (tia), and incident myocardial infarction
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strengths and limitations of this study
The currently available linked data assets comprise, to 
our knowledge, the world’s largest single population 
based cohort available for research, which will be 
further enhanced as further datasets are added. The 
availability of primary care data linked to such a 
wide range of other data is unparalleled at this scale, 
while the resource is also for the first time making 
linked nationwide covid-19 laboratory testing and 
community dispensing data available for research. 
Given that the linked cohort comprises more than 96% 
coverage of the English population, it represents the 
English population in terms of age, sex, ethnicity, and 
diabetes when compared with UK government official 
statistics for England,40-42 includes the full distribution 
of general practices according to geographical location 
and size,25 and includes large enough numbers of 
people with different characteristics to support a diverse 
range of statistically well powered research studies. For 
example, the cohort includes large numbers of: people 
in subgroups typically underrepresented in research 
(eg, several tens of thousands in each of the ethnic 
minority groups); younger people for whom poor 
outcomes of covid-19 are uncommon but nonetheless 
devastating (eg, almost 20 million people younger 
than 30 years, among whom 79 covid-19 related 
deaths were recorded by 31 October 2020); people 
experiencing the common exemplar cardiovascular 
outcomes of stroke or transient ischaemic attack 
and myocardial infarction (many tens of thousands), 
suggesting substantial potential to support studies 
on the impact of covid-19 on subtypes of stroke and 
myocardial infarction as well as on a wide range of rare 
conditions.
The NHS Digital TRE for England ensures secure, 
privacy protecting storage of and access to large 
volumes of data, while minimising the expense and 
security risks of data travel. Provision of data in this 
way is enabling a broad programme of collaborative 
research, encompassing several projects, which would 
be challenging to justify under the data dissemination 
model but which meet the relevant ethics and data 
access requirements under the trusted research 
environment model. Researchers from many different 
organisations have been able to gain rapid access 
to the linked datasets through the CVD-COVID-UK 
consortium and its data sharing agreement with 
NHS Digital, avoiding lengthy and costly processes 
for multiple separate organisational data access 
approvals and agreements. The consortium is enabling 
collaboration among researchers from across the UK, 
with a wide range of expertise (including clinicians 
from many different specialist backgrounds, data 
managers, computer scientists, data wranglers, 
epidemiologists, and biostatisticians). Furthermore, 
the consortium has encouraged productive interactions 
between researchers and NHS Digital staff (inclu-
ding project management, data management, data 
science, and technical development teams), enabling 
joint approaches to developing the trusted research 
environment service and to identifying and solving 
data provision and linkage challenges. The rich and 
diverse nature of this interdisciplinary collaboration 
supports clinically and methodologically informed 
data curation and analysis pipelines, and it will 
enhance the interpretation and clinical application of 
research outputs. Regular dataset updates ensure the 
contemporary relevance and dynamic nature of the data 
resource and will enable ongoing long term follow-up 
of the whole population. The development of publicly 
shareable, validated phenotyping algorithms19 and 
analytical code18 will avoid duplication of effort by 
additional groups of researchers working with the same 
or similar datasets. Although developed with the initial 
intent of supporting the CVD-COVID-UK consortium 
research programme, the NHS Digital TRE service for 
England has wider benefits, given its clear potential 
to expand to support research more broadly beyond 
covid-19 and beyond the cardiovascular domain. In 
addition, the work to establish the trusted research 
environment has generated knowledge about linked 






































fig 3 | Data sources reporting person level data on confirmed or suspected covid-19 diagnoses between 1 january 
2020 and 31 October 2020 (n=959 470). numbers indicate distinct people with a confirmed or suspected covid-19 
diagnosis
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data science research community, benefiting other UK-
wide initiatives, including the International Severe 
Acute Respiratory and Emerging Infection Consortium 
(ISARIC) study on the clinical characteristics of people 
admitted to hospital with covid-19,43 collaborative 
efforts to address the determinants of covid-19 
susceptibility, severity, and outcome through analyses 
of population based cohorts with biosamples linked 
to national EHRs44 45; the Randomised Evaluation of 
COVID-19 Therapy (RECOVERY) trial of treatments 
for covid-1946; the COVID-19 Genomics UK (COG-
UK) covid-19 viral sequencing study47; and the UK 
government chief scientific adviser’s national core 
studies programme, established to coordinate the 
UK’s covid-19 research response (in particular its 
underpinning data and connectivity theme led by 
Health Data Research UK).20
Nevertheless, limitations do exist: it is not yet 
possible to bring external cohort studies or trials 
into the environment for linkage (although data can 
be linked to these through NHS Digital’s standard 
data dissemination route); the primary care data are 
currently restricted to a large subset of SNOMED codes 
and limited to people known to be alive from November 
2019 onwards, although NHS Digital is currently 
enacting its plans to obtain a fully comprehensive 
primary care dataset, to be updated daily, which will 
become available during 2021 and will eventually 
replace the current primary care dataset; the trusted 
research environment currently has a relatively 
limited range of services and analytical tools, although 
NHS Digital is committed to expanding these; the 
descriptive results presented here provide an overview 
of the available resources with illustrative examples 
but are not designed to inform reliable conclusions 
about the associations between patient characteristics 
and covid-19 outcomes, as the analyses are unadjusted 
and so prone to confounding; information on the 
accuracy of the Master Patient Service matching at the 
level of each record within each dataset is needed to 
provide assurance of high linkage quality and to allow 
assessment of whether this varies by important patient 
characteristics, such as age, ethnicity, and deprivation; 
several previous studies have shown that nationally 
collated, coded health data from primary and 
secondary healthcare settings in the UK are sufficiently 
accurate for many research purposes, using a range 
of different validation approaches,48 49 but detailed, 
methodologically robust validation studies comparing 
contemporary linked UK routine data sources with 
expert adjudication based on the complete medical 
records for particular conditions are relatively rare, 
because they are time consuming, resource intensive, 
and challenging to perform50 51; while data quality 
checks have been performed on each dataset before 
creating the linked data resource, these vary by dataset 
(see supplementary figure 1, notes on data processing 
and quality checks) and future analyses might require 
additional checks to detect duplicates and minimise 
influential errors, outliers, and inconsistent records.
sustainability for the future
NHS Digital has already invested in the infrastructure 
of its Data Access Environment that supports the new 
trusted research environment service. Because this 
service is new, ongoing costs remain uncertain but 
will operate on the basis of cost recovery and will vary 
depending on numbers of datasets being accessed, 
number of researchers, software licensing costs, 
and compute usage. The costs of establishing and 
maintaining the trusted research environment and 
associated services for the CVD-COVID-UK consortium 
and research aligned to the UK government’s chief 
scientific officer’s national core studies programme 
are being met by the BHF Data Science Centre and 
funding from the national core studies programme. 
We anticipate that data access costs for future research 
will be met through a range of research funding routes 
(potentially including the National Institutes of Health 
Research, UK research councils, charities, industry, 
and others) given the considerable value and research 
potential of these data.
extending coverage across the four nations of  
the uK
The BHF Data Science Centre has also enabled access 
for members of the CVD-COVID-UK consortium to 
similar, albeit not identical, linked health data in 
separate, national trusted research environments in 
Scotland (Scottish National Data Safe Haven) and 
Wales (SAIL Databank), with plans to extend further to 
Northern Ireland.10 22 23 Thus we have already extended 
coverage to enable studies across a population of 
more than 65 million people, including the majority 
of people in the UK and increasing possibilities for 
geographical comparisons across the UK. Owing to 
differences in data structure and coding procedures 
between nations, we advocate the development of 
analysis plans that aim for maximum consistency 
but allow for these nation specific differences. When 
appropriate, results of nation specific analyses can be 
combined to produce UK-wide results. Such combined 
analyses will, increasingly, be able to take advantage 
of Health Data Research UK’s plans to provide the 
infrastructure, methods, and tools to enable federation 
of analyses across trusted research environments.52
conclusion
We describe provision for research of linked nation-
wide EHR data for England and show the importance 
of linking person level data from different health 
settings for defining exemplar CVD outcomes, covid-19 
diagnoses, and key characteristics. By covering almost 
the entire population of England, the resource 
includes all age groups, ethnicgroups, geographical 
locations, and socioeconomic, health, and personal 
characteristics, and it can enable statistically powerful 
population scale research with large numbers of 
outcomes. The resource is accessible to approved 
researchers through a secure trusted research environ-
ment hosted by NHS Digital to support research on 
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covid-19 and CVD, with plans to expand to benefit a 
broad range of research.
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